0001641640 false 00-0000000 00000 0001641640 2020-07-29 2020-07-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549








Date of Report (Date of Earliest Event Reported): July 29, 2020



(Exact name of registrant as specified in its charter)


Ireland   001-37558   Not Applicable
(State or other jurisdiction of
  (Commission File Number)   (I.R.S. Employer Identification


25-28 North Wall Quay,
IFSC, Dublin 1, Ireland
  Not Applicable
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (610) 816-6640


Not Applicable

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which
Ordinary Shares, nominal value $0.01 per share   NBRV   The Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


At the Annual General Meeting of Shareholders of Nabriva Therapeutics plc (the “Company”) held on July 29, 2020 (the “2020 Annual General Meeting”), the Company’s shareholders approved the 2020 Share Incentive Plan, as amended (the “2020 Plan”), which had previously been adopted by the Company’s board of directors subject to shareholder approval.


The description of the 2020 Plan contained on pages 37 to 52 of the Company’s Proxy Statement for the 2020 Annual General Meeting of Shareholders, filed with the Securities and Exchange Commission on June 25, 2020, is incorporated herein by reference. A complete copy of the 2020 Plan is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Item 5.07 Submission of Matters to a Vote of Security Holders.


At the 2020 Annual General Meeting, the Company’s shareholders voted on the following proposals:


(1) The Company’s shareholders elected the following nominees to serve as directors until the 2021 Annual General Meeting of Shareholders.


Name   For   Against   Abstain   Broker
Daniel Burgess   44,383,669   3,801,681   1,090,935   50,417,592  
Theodore Schroeder   44,024,364   4,632,671   619,250   50,417,592  
Colin Broom, M.D.   44,718,799   3,549,712   1,007,774   50,417,592  
Carrie Bourdow   43,681,892   4,388,715   1,205,678   50,417,592  
Charles A. Rowland, Jr.   44,230,313   4,076,182   969,790   50,417,592  
George H. Talbot, M.D.   44,552,867   3,811,302   912,116   50,417,592  
Stephen Webster   44,479,776   3,806,603   989,906   50,417,592  


(2)           The Company’s shareholders ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 and authorized, in a binding vote, the Company’s board of directors, acting through the audit committee, to set the independent registered public accounting firm’s remuneration.


For   Against   Abstain  
94,202,906   3,444,975   2,045,996  


(3)           The Company’s 2020 Share Incentive Plan, as amended, was approved.


For   Against   Abstain   Broker
42,682,810   5,492,319   1,101,156   50,417,592  


(4)           The Company’s proposal, subject to and conditional upon the board of directors determining, in its sole discretion, that a reverse stock split is necessary for the Company to comply with the minimum $1.00 per share requirement pursuant to Nasdaq Listing Rule 5450(a)(1), to effect a reverse stock split (i.e., a consolidation of share capital under Irish law) whereby every 10 ordinary shares of $0.01 (nominal value) each in the authorized and unissued and authorized and issued share capital of the Company be consolidated into 1 ordinary share of $0.10 (nominal value) each, and the subsequent reduction in the nominal value of the ordinary shares in the authorized and unissued and authorized and issued share capital of the Company from $0.10 each to $0.01 each, was approved.


For   Against   Abstain  
72,968,843   26,323,697   401,337  


Item 9.01. Financial Statements Exhibits.


(d) Exhibits


99.1 2020 Share Incentive Plan, as amended







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: July 29, 2020 By:   /s/ Gary Sender
    Gary Sender
    Chief Financial Officer



Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Nabriva Therapeutics Charts.
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Nabriva Therapeutics Charts.